Document is current
Any future updates will be listed below
-
Authors
Schelker, Roland C.
Fioravanti, Jessica https://orcid.org/0000-0001-6263-4306
Mastrogiovanni, Fabio
Baldwin, Jeremy G.
Rana, Nisha
Li, Peng
Chen, Ping
Vadász, Timea
Spolski, Rosanne
Heuser-Loy, Christoph https://orcid.org/0000-0003-1410-7573
Slavkovic-Lukic, Dragana https://orcid.org/0000-0002-3107-7727
Noronha, Pedro
Damiano, Giuseppe
Raccosta, Laura
Maggioni, Daniela
Pullugula, Sree
Lin, Jian-Xin https://orcid.org/0000-0001-5849-9412
Oh, Jangsuk
Grandinetti, Patrick
Lecce, Mario
Hesse, Leo
Kocks, Emilia
Martín-Santos, Azucena
Gebhard, Claudia
Telford, William G.
Ji, Yun
Restifo, Nicholas P.
Russo, Vincenzo
Rehli, Michael
Herr, Wolfgang
Leonard, Warren J. https://orcid.org/0000-0002-5740-7448
Gattinoni, Luca https://orcid.org/0000-0003-2239-3282
- License Information
-
More Information
Article History
Received: 1 December 2023
Revised: 13 June 2024
Accepted: 4 July 2024
First Online: 9 August 2024
Competing interests
: L.G. has consulting agreements with Lyell Immunopharma Inc. L.G. is on the scientific advisory board of Poseida Therapeutics and Kiromic, and a stockholder of Poseida Therapeutics. J.F. is an employee and owns stock in Lyell Immunopharma, Inc. All other authors declare no competing interests.
